| Gerald Mingin, MD | |
|
111 Colchester Ave, Mail Stop 320 Fl, Burlington, VT 05401-1473 | |
| (802) 847-2194 | |
| (802) 847-4937 |
| Full Name | Gerald Mingin |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 30 Years |
| Location | 111 Colchester Ave, Burlington, Vermont |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447344775 | NPI | - | NPPES |
| 1013484 | Medicaid | VT | |
| 02881001 | Medicaid | NY | |
| 30207298 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2088P0231X | Urology - Pediatric Urology | 255644 (New York) | Secondary |
| 2088P0231X | Urology - Pediatric Urology | 0420011293 (Vermont) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Vermont Medical Center Inc | 3779491071 | 994 |
News Archive
Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the second quarter and the first six months ended June 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.
In a discovery that could point to new treatments for a wide range of neurodegenerative diseases, Jackson Laboratory researchers have found that high-dose radiation and bone marrow transfer treatments on glaucoma-susceptible mice completely blocked the development of glaucoma, by preventing neurodegeneration.
HORIBA UK Ltd, Medical announces the publication of two studies successfully evaluating the use of its Yumizen H500 hematology analyzer for point-of-care testing to enhance the care of oncology patients.
Haemonetics Corporation today reported second quarter 2012 GAAP net revenues of $179.4 million, up 8%, net income of $13.9 million, down 35%, and earnings per share of $0.54, down 36%. Excluding transformation costs and contingent consideration income, adjusted second quarter net income was $18.7 million, down 7%, and adjusted earnings per share was $0.72, down 9%. Excluding currency impacts, net revenue was up 6% in the quarter.
Today, leading California Neurotechnology company NeuroVigil and Swiss Pharma giant Roche announced an agreement regarding a major innovation in collecting and analyzing data from clinical trials.
› Verified 5 days ago
| Entity Name | University Of Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the second quarter and the first six months ended June 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.
In a discovery that could point to new treatments for a wide range of neurodegenerative diseases, Jackson Laboratory researchers have found that high-dose radiation and bone marrow transfer treatments on glaucoma-susceptible mice completely blocked the development of glaucoma, by preventing neurodegeneration.
HORIBA UK Ltd, Medical announces the publication of two studies successfully evaluating the use of its Yumizen H500 hematology analyzer for point-of-care testing to enhance the care of oncology patients.
Haemonetics Corporation today reported second quarter 2012 GAAP net revenues of $179.4 million, up 8%, net income of $13.9 million, down 35%, and earnings per share of $0.54, down 36%. Excluding transformation costs and contingent consideration income, adjusted second quarter net income was $18.7 million, down 7%, and adjusted earnings per share was $0.72, down 9%. Excluding currency impacts, net revenue was up 6% in the quarter.
Today, leading California Neurotechnology company NeuroVigil and Swiss Pharma giant Roche announced an agreement regarding a major innovation in collecting and analyzing data from clinical trials.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gerald Mingin, MD 111 Colchester Ave, Mail Stop 320 Fl, Burlington, VT 05401-1473 Ph: (802) 847-2194 | Gerald Mingin, MD 111 Colchester Ave, Mail Stop 320 Fl, Burlington, VT 05401-1473 Ph: (802) 847-2194 |
News Archive
Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the second quarter and the first six months ended June 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.
In a discovery that could point to new treatments for a wide range of neurodegenerative diseases, Jackson Laboratory researchers have found that high-dose radiation and bone marrow transfer treatments on glaucoma-susceptible mice completely blocked the development of glaucoma, by preventing neurodegeneration.
HORIBA UK Ltd, Medical announces the publication of two studies successfully evaluating the use of its Yumizen H500 hematology analyzer for point-of-care testing to enhance the care of oncology patients.
Haemonetics Corporation today reported second quarter 2012 GAAP net revenues of $179.4 million, up 8%, net income of $13.9 million, down 35%, and earnings per share of $0.54, down 36%. Excluding transformation costs and contingent consideration income, adjusted second quarter net income was $18.7 million, down 7%, and adjusted earnings per share was $0.72, down 9%. Excluding currency impacts, net revenue was up 6% in the quarter.
Today, leading California Neurotechnology company NeuroVigil and Swiss Pharma giant Roche announced an agreement regarding a major innovation in collecting and analyzing data from clinical trials.
› Verified 5 days ago
Eric Richmond Sargent, M.D. Urology Medicare: Medicare Enrolled Practice Location: 111 Colchester Avenue, East Pavilion 5, Burlington, VT 05401 Phone: 802-847-2884 Fax: 802-847-6020 | |
Elizabeth Ann Stampfl, PA Urology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, East Pavilion-level 5-urology, Burlington, VT 05401 Phone: 802-847-2884 Fax: 802-847-6020 | |
Andrew C Mahoney, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 407-847-4097 | |
Benjamin King, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave # Ep-5, Burlington, VT 05401 Phone: 802-847-2884 | |
Dr. Mark Kenneth Plante, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, East Pavilion-level 5 Urology, Burlington, VT 05401 Phone: 802-847-2884 Fax: 802-847-6020 | |
John A Bisson, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 64 Colchester Ave, Burlington, VT 05401 Phone: 802-863-0107 Fax: 802-658-9292 | |
Richard T Grunert, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-4097 |